• Product NameTRx0237 (LMTX) mesylate
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityTRx 0237 (LMTX?) mesylate is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia.
• Target NameMicrotubule Associated inhibitor
• CAS No. 1236208-20-0
• Calculated MW 477.62
• Formulation C16H19N3S2CH4O3S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CS([O-])(=O)=O.CS([O-])(=O)=O.C[NH+](C)C1=CC=C2NC3=C(SC2=C1)C=C(C=C3)[NH+](C)C |c:16,20,23,25,t:11,13|
  Pathways:Cytoskeletal Signaling
  Receptor:Tau aggregation
  Boling pt:
  Melting pt:
  Solubility:Ethanol<1 mg/mLDMSO: 95 mg/mL (198.9 mM)Water: 95 mg/mL (198.9 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Panza F.,Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy? Expert Opin Pharmacother. 2016;17(4):457-61.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting